Kido Jun, Matsumoto Shirou, Momosaki Ken, Sakamoto Rieko, Mitsubuchi Hiroshi, Inomata Yukihiro, Endo Fumio, Nakamura Kimitoshi
Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto City, Japan.
Department of Transplantation and Pediatric Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto City, Japan.
Hepatol Res. 2017 Mar;47(4):359-363. doi: 10.1111/hepr.12711. Epub 2016 May 28.
Wilson disease (WD) in patients with a New Wilson Index (NWI) score ≥ 11 is fatal, and these patients are good candidates for liver transplantation (LT). However, plasma exchange and chelator therapy are indispensable and effective even for WD with a score ≥ 11. Moreover, continuous hemodiafiltration (CHDF) with these treatments is essential for acute liver failure (ALF) in WD with hepatic encephalopathy because CHDF can exclude toxic metabolites that may cause damage to the brain. Here, we describe four rescued patients presenting with ALF in WD and discuss the available treatment options.
We have experienced 11 male and 8 female patients presenting with WD at the Department of Pediatrics, Kumamoto University Hospital between 1999 and 2014. A male and 4 female patients were diagnosed as WD with ALF using a combination of clinical findings and biochemical tests.
The NWI score was ≥ 11 in cases 1 to 3. Cases 1 and 2 with hepatic encephalopathy received plasma exchange, CHDF, coagulation factor replacement treatment (CFRT) and LT. Cases 3 and 4 without encephalopathy obtained stable status without LT by plasma exchange, blood infusion, and CFRT.
It is better to undergo LT for WD patients with a NWI score ≥ 11, however, there is a possibility of remission by plasma exchange and medical therapy even without LT. WD patients with a NWI score ≥ 11can be rescued by conservative therapy when the ALF of WD does not present with ALF and hepatic encephalopathy. Therefore, ALF with hepatic encephalopathy itself is an indication for LT in WD.
新威尔逊指数(NWI)评分≥11的威尔逊病(WD)患者病情凶险,是肝移植(LT)的良好候选者。然而,血浆置换和螯合剂治疗即便对于NWI评分≥11的WD患者也是不可或缺且有效的。此外,对于伴有肝性脑病的WD急性肝衰竭(ALF)患者,在这些治疗基础上进行持续血液透析滤过(CHDF)至关重要,因为CHDF可清除可能损害大脑的毒性代谢产物。在此,我们描述4例WD合并ALF且成功获救的患者,并讨论可用的治疗方案。
1999年至2014年期间,熊本大学医院儿科共收治11例男性和8例女性WD患者。1例男性和4例女性患者通过临床症状和生化检查确诊为WD合并ALF。
病例1至3的NWI评分≥11。病例1和2伴有肝性脑病,接受了血浆置换、CHDF、凝血因子替代治疗(CFRT)及LT。病例3和4无脑病,通过血浆置换、输血及CFRT未行LT即获得病情稳定。
NWI评分≥11的WD患者最好接受LT,然而,即便不进行LT,通过血浆置换和药物治疗也有缓解的可能。当WD合并的ALF未出现肝性脑病时,NWI评分≥11的WD患者可通过保守治疗获救。因此,伴有肝性脑病的ALF本身是WD患者LT的指征。